Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Carolina Schinke to Multiple Myeloma

This is a "connection" page, showing publications Carolina Schinke has written about Multiple Myeloma.

 
Connection Strength
  
 
 
8.482
  
  1. Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T, Le HH, DeBrosse A, Okorozo P, McDowell R, Patel S, Bunn J, Hawks K, Zhang X, Rodriguez C. Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers. Curr Med Res Opin. 2024 Oct; 40(10):1705-1711.
    View in: PubMed
    Score: 0.343
  2. Mohan M, Schinke C. Risk stratification in multiple myeloma: Are we there yet? Br J Haematol. 2024 May; 204(5):1585-1587.
    View in: PubMed
    Score: 0.334
  3. Schinke C. The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma. Chin Clin Oncol. 2024 Jun; 13(3):45.
    View in: PubMed
    Score: 0.332
  4. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 03 01; 109(3):906-914.
    View in: PubMed
    Score: 0.331
  5. Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024 May; 59(5):647-652.
    View in: PubMed
    Score: 0.330
  6. Schinke C, Rasche L, Raab MS, Weinhold N. Impact of Clonal Heterogeneity in Multiple Myeloma. Hematol Oncol Clin North Am. 2024 04; 38(2):461-476.
    View in: PubMed
    Score: 0.328
  7. Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies F, Raab MS, Morgan G, Weinhold N. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022 11 22; 6(22):5873-5883.
    View in: PubMed
    Score: 0.303
  8. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 12; 97(12):E451-E453.
    View in: PubMed
    Score: 0.300
  9. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280.
    View in: PubMed
    Score: 0.292
  10. Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 06 01; 97(6):E195-E198.
    View in: PubMed
    Score: 0.290
  11. Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 12 01; 106(12):3215-3218.
    View in: PubMed
    Score: 0.284
  12. Schinke CD, Bird JT, Qu P, Yaccoby S, Lyzogubov VV, Shelton R, Ling W, Boyle EM, Deshpande S, Byrum SD, Washam C, Mackintosh S, Stephens O, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Barlogie B, van Rhee F, Walker BA. PHF19 inhibition as a therapeutic target in multiple myeloma. Curr Res Transl Med. 2021 07; 69(3):103290.
    View in: PubMed
    Score: 0.272
  13. Mohan M, Yarlagadda N, Szabo A, Singh A, Pina Oviedo S, Schinke C. Clinical characteristics of testicular extramedullary involvement in multiple myeloma. Am J Hematol. 2021 03 01; 96(3):E77-E81.
    View in: PubMed
    Score: 0.266
  14. Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clin Cancer Res. 2018 06 15; 24(12):2913-2919.
    View in: PubMed
    Score: 0.219
  15. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017 Aug; 92(8):739-745.
    View in: PubMed
    Score: 0.208
  16. Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 08; 102(8):e313-e316.
    View in: PubMed
    Score: 0.207
  17. Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood Cancer J. 2024 Aug 12; 14(1):137.
    View in: PubMed
    Score: 0.085
  18. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224.
    View in: PubMed
    Score: 0.085
  19. Went M, Duran-Lozano L, Halldorsson GH, Gunnell A, Ugidos-Damboriena N, Law P, Ekdahl L, Sud A, Thorleifsson G, Thodberg M, Olafsdottir T, Lamarca-Arrizabalaga A, Cafaro C, Niroula A, Ajore R, Lopez de Lapuente Portilla A, Ali Z, Pertesi M, Goldschmidt H, Stefansdottir L, Kristinsson SY, Stacey SN, Love TJ, Rognvaldsson S, Hajek R, Vodicka P, Pettersson-Kymmer U, Sp?th F, Schinke C, Van Rhee F, Sulem P, Ferkingstad E, Hjorleifsson Eldjarn G, Mellqvist UH, Jonsdottir I, Morgan G, Sonneveld P, Waage A, Weinhold N, Thomsen H, F?rsti A, Hansson M, Juul-Vangsted A, Thorsteinsdottir U, Hemminki K, Kaiser M, Rafnar T, Stefansson K, Houlston R, Nilsson B. Deciphering the genetics and mechanisms of predisposition to multiple myeloma. Nat Commun. 2024 Aug 05; 15(1):6644.
    View in: PubMed
    Score: 0.085
  20. Sabol HM, Ashby C, Adhikari M, Anloague A, Kaur J, Khan S, Choudhury SR, Schinke C, Palmieri M, Barnes CL, Ambrogini E, Nookaew I, Delgado-Calle J. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024 08 01; 109(8):2606-2618.
    View in: PubMed
    Score: 0.085
  21. Thalambedu N, Farmer P, Bailey C, Yarlagadda L, Al-Hadidi S, Thanendrarajan S, Zangari M, Schinke C, VanRhee F. CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
    View in: PubMed
    Score: 0.083
  22. Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, D'Souza A, Mohan M. Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. Blood Cancer J. 2024 Mar 05; 14(1):36.
    View in: PubMed
    Score: 0.083
  23. Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024 Mar 05; 14(1):35.
    View in: PubMed
    Score: 0.083
  24. Guo W, Zhan Y, Mery D, Siegel ER, Sun F, Cheng Y, Ashby TC, Zhang Z, Bailey C, Alapat DV, Peng H, Hadidi SA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood Cancer J. 2024 02 14; 14(1):30.
    View in: PubMed
    Score: 0.083
  25. Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024 02 13; 8(3):703-707.
    View in: PubMed
    Score: 0.083
  26. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
    View in: PubMed
    Score: 0.082
  27. Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 Jan 02; 134(1).
    View in: PubMed
    Score: 0.082
  28. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214.
    View in: PubMed
    Score: 0.081
  29. Kleman A, Singavi A, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns R, Steinhardt GF, Rao S, Carlson K. A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Blood Adv. 2023 09 26; 7(18):5549-5553.
    View in: PubMed
    Score: 0.080
  30. Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, Fu AZ, Lafeuille MH, Thompson-Leduc P, Khare V, Reitan J, Milkovich G, Kaila S, Davies F, Usmani SZ. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. Clin Lymphoma Myeloma Leuk. 2024 01; 24(1):55-63.
    View in: PubMed
    Score: 0.080
  31. Lin M, Estrada-Merly N, Eapen M, Zamora AE, Pezzin LE, Winn AN, Philip J, Schinke C, Drobyski WR, Anderson LD, D'Souza A. Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States. Bone Marrow Transplant. 2023 12; 58(12):1400-1402.
    View in: PubMed
    Score: 0.080
  32. John L, Poos AM, Brobeil A, Schinke C, Huhn S, Prokoph N, Lutz R, Wagner B, Zangari M, Tirier SM, Mallm JP, Schumacher S, Vonficht D, Sol?-Boldo L, Quick S, Steiger S, Przybilla MJ, Bauer K, Baumann A, Hemmer S, Rehnitz C, L?ckerath C, Sachpekidis C, Mechtersheimer G, Haberkorn U, Dimitrakopoulou-Strauss A, Reichert P, Barlogie B, M?ller-Tidow C, Goldschmidt H, Hillengass J, Rasche L, Haas SF, van Rhee F, Rippe K, Raab MS, Sauer S, Weinhold N. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nat Commun. 2023 08 17; 14(1):5011.
    View in: PubMed
    Score: 0.080
  33. Fahmawi S, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. J Cancer Policy. 2023 09; 37:100433.
    View in: PubMed
    Score: 0.079
  34. Mehdi SJ, Ghatak K, Ling W, Johnson SK, Epstein J, Nookaew I, Zangari M, Schinke C, Thanendrarajan S, van Rhee F, Yaccoby S. Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leuk Res. 2023 10; 133:107355.
    View in: PubMed
    Score: 0.079
  35. Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 07 11; 7(13):3069-3074.
    View in: PubMed
    Score: 0.079
  36. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70.
    View in: PubMed
    Score: 0.079
  37. Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498.
    View in: PubMed
    Score: 0.079
  38. Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 04; 58(4):443-445.
    View in: PubMed
    Score: 0.076
  39. Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022 09 15; 132(18).
    View in: PubMed
    Score: 0.075
  40. Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, Poos AM, Zangari M, Thanendrarajan S, Davies FE, Walker BA, Barlogie B, Landgren O, Morgan GJ, van Rhee F, Weinhold N. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022 08 03; 13(1):4517.
    View in: PubMed
    Score: 0.074
  41. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877.
    View in: PubMed
    Score: 0.074
  42. Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022 02 08; 6(3):808-817.
    View in: PubMed
    Score: 0.072
  43. Yarlagadda N, Gundarlapalli S, Sharma S, Suelzer E, Abid MB, Abdallah AO, Schinke C, Atrash S, Mohan M. Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. Leuk Res. 2021 11; 110:106714.
    View in: PubMed
    Score: 0.070
  44. Boyle EM, Rosenthal A, Ghamlouch H, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Wang Y, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Dhodapkar MV, Davies FE, Morgan GJ, van Rhee F, Walker BA. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2022 02; 36(2):591-595.
    View in: PubMed
    Score: 0.069
  45. Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Davies FE, Walker BA, van Rhee F, Morgan GJ. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. Br J Haematol. 2021 10; 195(2):283-286.
    View in: PubMed
    Score: 0.069
  46. Mohan M, Szabo A, Yarlagadda N, Gundarlapalli S, Thanendrarajan S, Kendrick S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. Am J Hematol. 2021 09 01; 96(9):E341-E344.
    View in: PubMed
    Score: 0.069
  47. Mohan M, Kumar M, Samant R, Van Hemert R, Tian E, Desai S, van Rhee F, Thanendrarajan S, Schinke C, Suva LJ, Sharma S, Milad M, Kendrick S, Zangari M. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 05; 146:115876.
    View in: PubMed
    Score: 0.067
  48. Deshpande S, Tytarenko RG, Wang Y, Boyle EM, Ashby C, Schinke CD, Thanendrarajan S, Zangari M, Zhan F, Davies FE, Morgan GJ, van Rhee F, Walker BA. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. Eur J Haematol. 2021 Feb; 106(2):230-240.
    View in: PubMed
    Score: 0.066
  49. Choudhury SR, Ashby C, Tytarenko R, Bauer M, Wang Y, Deshpande S, Den J, Schinke C, Zangari M, Thanendrarajan S, Davies FE, van Rhee F, Morgan GJ, Walker BA. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020 08 06; 13(1):108.
    View in: PubMed
    Score: 0.065
  50. Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Danziger SA, Ratushny A, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 07; 34(7):1866-1874.
    View in: PubMed
    Score: 0.063
  51. Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, Schinke C, Thanendrarajan S, Davies FE, Hoering A, Morgan GJ. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020 Jan 28; 4(2):422-431.
    View in: PubMed
    Score: 0.062
  52. Boyle EM, Ashby C, Tytarenko RG, Deshpande S, Wang H, Wang Y, Rosenthal A, Sawyer J, Tian E, Flynt E, Hoering A, Johnson SK, Rutherford MW, Wardell CP, Bauer MA, Dumontet C, Facon T, Thanendrarajan S, Schinke CD, Zangari M, van Rhee F, Barlogie B, Cairns D, Jackson G, Thakurta A, Davies FE, Morgan GJ, Walker BA. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clin Cancer Res. 2020 05 15; 26(10):2422-2432.
    View in: PubMed
    Score: 0.062
  53. Sridharan A, Schinke CD, Georgiev G, Da Silva Ferreira M, Thiruthuvanathan V, MacArthur I, Bhagat TD, Choudhary GS, Aluri S, Chen J, Pradhan K, Xia Y, Panjikaran M, Sims G, Bhagat CK, Bender R, Keeler L, Graber A, Heuck C, Fletcher FA, Alapat D, Weinhold N, Johnson SK, Wickrema A, Barlogie B, Morgan GJ, Shastri A, Steidl U, Will B, Verma A. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019 12 10; 3(23):3962-3967.
    View in: PubMed
    Score: 0.062
  54. Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR, Tian E, van Rhee F, Zangari M. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol. 2020 04; 189(1):67-71.
    View in: PubMed
    Score: 0.062
  55. Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, Bailey C, Schinke CD, Thanendrarajan S, Davies FE, Morgan GJ, Barlogie B, Zangari M, van Rhee F. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer J. 2019 08 09; 9(8):62.
    View in: PubMed
    Score: 0.060
  56. Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, Lapa C, Bley T, Buck A, McDonald J, Hillengass J, Epstein J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis? Theranostics. 2019; 9(16):4756-4763.
    View in: PubMed
    Score: 0.060
  57. Mohan M, Susanibar-Adaniya S, Buros A, Crescencio JCR, Burgess MJ, Lusardi K, Davies F, Morgan G, Vanrhee F, Zangari M, Schinke C, Thanendrarajan S, Kothari A. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transpl Infect Dis. 2019 Apr; 21(2):e13052.
    View in: PubMed
    Score: 0.058
  58. Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2019 02; 184(4):578-593.
    View in: PubMed
    Score: 0.057
  59. Atrash S, Dua I, Buros AF, Van Rhee F, Suva LJ, Thanendrarajan S, Schinke C, Davies F, Morgan G, Zangari M. FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone. 2019 04; 121:134-138.
    View in: PubMed
    Score: 0.057
  60. Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018 07 05; 132(1):59-66.
    View in: PubMed
    Score: 0.056
  61. Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 11; 32(11):2435-2444.
    View in: PubMed
    Score: 0.055
  62. Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018 06; 103(6):1047-1053.
    View in: PubMed
    Score: 0.055
  63. Mathur P, Thanendrarajan S, Paydak H, Vallurupalli S, Jambhekar K, Bhatti S, Schinke CD, Davies FE, Mehta JL. Cardiovascular complications of multiple myeloma in the elderly. Expert Rev Cardiovasc Ther. 2017 Dec; 15(12):933-943.
    View in: PubMed
    Score: 0.054
  64. Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 09; 102(9):e364-e367.
    View in: PubMed
    Score: 0.052
  65. Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 07 06; 130(1):30-34.
    View in: PubMed
    Score: 0.051
  66. Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res. 2017 Jun; 32(6):1261-1266.
    View in: PubMed
    Score: 0.051
  67. Mohan M, Fogel B, Eluvathingal T, Schinke C, Kothari A. Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma. Transpl Infect Dis. 2016 Dec; 18(6):939-941.
    View in: PubMed
    Score: 0.050
  68. McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res. 2017 04 15; 23(8):1981-1987.
    View in: PubMed
    Score: 0.050
  69. Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 09 29; 128(13):1735-44.
    View in: PubMed
    Score: 0.049
  70. Boota M, Schinke C, Ledoux S, Alapat D, Khan R, Barlogie B. CA-125 secreting IgG kappa multiple myeloma. Am J Hematol. 2016 Oct; 91(10):E457-8.
    View in: PubMed
    Score: 0.049
  71. Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84.
    View in: PubMed
    Score: 0.047
  72. Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013 Mar 15; 190(6):2966-75.
    View in: PubMed
    Score: 0.039
  73. Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.